Uniunea Europeană - română - EMA (European Medicines Agency)

mylan ireland limited - lenalidomidă - mielom multiplu - imunosupresoare - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Uniunea Europeană - română - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - imunosupresoare - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

janssen pharmaceutica nv - belgia - bortezomibum - pulb. pt. sol. inj. - 1mg - alte antineoplazice inhibitori de proteazom

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

janssen pharmaceutica nv - belgia - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice inhibitori de proteazom

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - pomalidomide - mielom multiplu - imunosupresoare - imnovid în asociere cu bortezomib și dexametazonă este indicat în tratamentul pacienților adulți cu mielom multiplu care au primit anterior cel puțin un tratament inclusiv lenalidomidă. imnovid în combinaţie cu dexametazona este indicat în tratamentul pacienţilor adulţi cu mielom multiplu recidivat si refractar, care au primit cel puţin două regimuri de tratament anterior, inclusiv atât lenalidomidă şi bortezomib, şi au demonstrat progresia bolii pe ultima terapie.

Uniunea Europeană - română - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - mielom multiplu - agenți antineoplazici - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - lenalidomidum - caps. - 20mg - imunosupresoare alte imunosupresoare

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - lenalidomidum - caps. - 5mg - imunosupresoare alte imunosupresoare